Long-term outcomes in the second-line treatment of chronic myeloid leukemia: A review of tyrosine kinase inhibitors

Cancer

Volumn 117, Issue 5, 2011, Pages 897-906

  Jabbour, Elias ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; Second line therapy

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BILIRUBIN; CYTARABINE; DASATINIB; IMATINIB; LIVER ENZYME; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER RESISTANCE; CANCER STAGING; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FLUID RETENTION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; LOW DRUG DOSE; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952022701     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25656     Document Type: Review

References (71)

1. Ramchandren R, Schiffer CA. Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia. Biologics. 2009; 3:205-214.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999; 340:1330-1340. (Pubitemid 29196596)
3. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007;357: 258-265. (Pubitemid 47080390)
4. Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol. 2009;4:3-10.
5. Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol. 2007;44:S4-S14.
6. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132: 1497-1464.
7. Rowley JD. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
8. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006;81:973-988.
9. Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18: 671-684. (Pubitemid 38969138)
10. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
11. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037. (Pubitemid 32267972)
12. Wong SF. New dosing schedules of dasatinib for CML and adverse event management. J Hematol Oncol. 2009;23:2-10.
13. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551. (Pubitemid 43882350)
14. Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
15. Deininger M, O'Brien S, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1126.
16. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients 534 receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
17. Mauro MJ. Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program. 2006:219-225.
18. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2.2010. Jenkintown, Pa: NCCN; 2009. http://www.nccn.org/professionals/physician-gls/PDF/ cml.pdf. Accessed September 24, 2009.
19. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27: 6041-6051.
20. Lee F, Fandi A, Voi M. Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol. 2008;40: 334-343. (Pubitemid 351241231)
21. Branford S, Rudzki Z, Walsh S, et al. Detection of BCRABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283. (Pubitemid 36759665)
22. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767-1773. (Pubitemid 44574988)
23. O'Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-Year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 186.
24. Hamdan MY, Sanders L, Oliveria S, et al. Discontinuation and dose modification of imatinib in clinical practice [abstract]. J Clin Oncol. 2007;25(18S). Abstract 7045.
25. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539. (Pubitemid 34534519)
26. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937. (Pubitemid 34525471)
27. Kantarjian H, Sawyers C, Hochhaus A, et al; International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652. (Pubitemid 34815868)
28. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473-475. (Pubitemid 36077567)
29. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003;102:2702-2703.
30. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res. 2003;9: 2092-2097. (Pubitemid 36687630)
31. Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: 2-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009;115:4136-4147.
32. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
33. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
34. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
35. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401. (Pubitemid 38938156)
36. Ramirez P, Dipersio JF. Therapy options in imatinib failures. Oncologist. 2008;13:424-434. (Pubitemid 351679922)
37. Deininger MW. Nilotinib. Clin Cancer Res. 2008;14:4027-4031.
38. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-3213. (Pubitemid 46572505)
39. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109:4143-4150. (Pubitemid 46743375)
40. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:2303-2309. (Pubitemid 46425867)
41. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 110:2309-2315. (Pubitemid 47523149)
42. Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 7009.
43. Baccarani M, Rost G, Saglio G, et al. Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 450.
44. Rea D, Dombret H, Kim DW, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in accelerated phase 24-month data from START-A [abstract]. Haematologica. 2008;93(suppl 1):391. Abstract 0982.
45. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204-3212.
46. Stone RM, Kim DW, Kantarjian HM, et al. Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS) [abstract]. J Clin Oncol. 2009;27(15s). Abstract 7007.
47. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113:6322-6329.
48. Saglio G, Kantarjian HM, Hochhaus A, et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-year data from CA180-035 [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 3226.
49. Larson RA, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily (QD) has equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 2-year data from CA180-035 [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 2926.
50. Shah NP, Bahceci E, Lambert A, Ploughman L, Radich J. Resistance, outcome and the development of mutations with dasatinib in patients with chronic-phase chronic myeloid leukemia (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1122.
51. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003; 101:3794-3800. (Pubitemid 36857848)
52. O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood. 2004;103:451-455. (Pubitemid 38140072)
53. Fabarius A, Haferlach C, Muller MC, et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica. 2007;92:834-837. (Pubitemid 350155309)
54. Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010;24:1299-1301.
55. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141. (Pubitemid 40248339)
56. Kantarjian H, Giles FG, Bhalla KNP, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study [abstract]. Haematologica. 2009;94(suppl 2):254. Abstract 0627.
57. Kantarjian H, Giles F, Bhalla K, et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1129.
58. Hochhaus A, Giles F, Apperely J, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study [abstract]. Haematologica. 2009; 94(suppl 2):256. Abstract 0631.
59. Kantarjian H, Giles FG, Bhalla KNP, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year followup results of a phase 2 study [abstract]. Blood. 2008;112. Abstract 3238.
60. Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;109:497-499. (Pubitemid 46105944)
61. Cannella L, Breccia M, Stefanizzi C, et al. Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance. Leuk Lymphoma. 2009;50:848-850.
62. Shah NP, Kim D-W, Kantarjian HM, et al. Dasatinib dose-optimization in chronic phase chronic myeloid leukemia (CML-CP): 2-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 3225.
63. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of frontline imatinib: a randomized phase 2 trial. Blood. 2007;109:5143-5150. (Pubitemid 46890528)
64. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110:4005-4011. (Pubitemid 350248456)
65. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008;112:53-55.
66. Soverini S, Martinelli G, Colarossi S, et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. Blood. 2006;24:e51-e52.
67. Jabbour E, Jones D, Kantarjian HM, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCRABL kinase domain mutations. Blood. 2009;114:2037-2043.
68. Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009;114:4944-4953.
69. Kantarjian HM, Jabbour E, Giles FJ, et al. Prognostic factors for progression-free survival in patients with imatinibresistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib based on 24 month data. Blood. 2009;113:3298.
70. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12:7374-7379. (Pubitemid 46095411)
71. Quintas-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009;115:2482-2490.